Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 12/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4815015 | 1.00 | PTGER1 (0.41) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4817695 | 0.89 | PTGER1 (0.40) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL4817702 | 0.89 | PTGER1 (0.40) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL4809778 | 0.86 | SLC5A2 (0.38) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4809775 | 0.86 | SLC5A2 (0.38) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4807931 | 0.84 | SLC5A2 (0.36) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL4807926 | 0.84 | SLC5A2 (0.36) | PTGER1CYP2C9CYP2C19CYP1A2TBXA2R | |
| SCHEMBL4817939 | 0.84 | PTGER1 (0.35) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4817946 | 0.84 | PTGER1 (0.35) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL4813331 | 0.83 | HTR2C (0.39) | PTGER1CYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | PTGER1 3048/4885CYP2C9 1076/4885CYP2C19 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.